Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Afamelanotide

If you want to know more about the Afamelanotide, the following articles will give you some help. These news is the latest market situation, trend in development, or related tips of the Afamelanotide industry. More news about Afamelanotide, are being released. Follow us / contact us for more Afamelanotide information!
  • Drug Patent & Exclusivity Expiration Report - Week of Feb 10 2025

    Drug Patent & Exclusivity Expiration Report - Week of Feb 10 2025

    2025-02-10

    This week, there are 6 drugs in the patent and exclusivity list. They are: - Tudorza Pressair by Covis Pharma GMBH, containing active ingredient Aclidinium Bromide - Duaklir Pressair by Covis Pharma GMBH, containing active ingredient Aclidinium Bromide and Formoterol Fumarate - Scenesse by Clinuvel Inc, containing active ingredient Afamelanotide - Hysingla ER by Purdue Pharma LP, containing active ingredient Hydrocodone Bitartrate - Izervay by Astellas Pharma US Inc, containing active ingredient Avacincaptad Pegol Sodium - Symdeko by Vertex Pharmaceuticals Inc, containing active ingredient Ivacaftor and Tezacaftor Read More